Apr 20, 2026 06:45AM
Apr 20, 2026 06:45AM
Mar 23, 2026 04:29AM
Feb 27, 2026 10:04AM
Feb 27, 2026 10:00AM
Feb 23, 2026 05:00PM
Dec 17, 2025 06:45AM PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Nov 21, 2025 01:24PM
Nov 21, 2025 01:24PM
Oct 18, 2025 10:30AM
Aug 12, 2025 05:30AM
Jul 17, 2025 12:00AM
Jul 17, 2025 12:00AM
May 22, 2025 05:00PM Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Feb 12, 2025 06:32PM
Feb 10, 2025 05:01PM
Feb 10, 2025 05:00PM
Jan 8, 2025 06:30PM
May 21, 2024 12:00AM
Jan 26, 2024 12:01PM
Jan 26, 2024 12:00PM European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Jan 26, 2024 12:00PM
Jan 8, 2024 06:30PM
Dec 21, 2023 06:30PM
Nov 16, 2023 10:33PM
Nov 15, 2023 06:37PM
Aug 23, 2023 06:45AM
Apr 30, 2023 09:24PM Astellas Pharma to acquire Iveric Bio (ISEE) for $5.9 billion
Apr 30, 2023 07:00PM
Apr 29, 2023 10:45AM
Mar 16, 2023 07:30PM
Feb 19, 2023 06:30PM
Aug 18, 2022 02:30AM
Sep 20, 2021 05:46AM
Sep 17, 2021 06:05PM Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study
May 29, 2020 08:20AM
May 29, 2020 08:00AM
Jan 14, 2020 02:07AM
Dec 26, 2019 07:30PM
Nov 20, 2019 08:00PM
Oct 1, 2019 05:00AM
Aug 10, 2018 07:00AM Astellas Announces Acquisition of Quethera
Apr 25, 2018 11:00PM
Feb 13, 2018 08:00PM
Jan 30, 2018 10:00PM
Jan 23, 2018 09:00PM
Nov 30, 2017 07:00PM
Oct 30, 2017 11:09PM
Jul 27, 2017 11:05PM Astellas Reports First Quarter FY2017 Financial Results
Apr 26, 2017 11:06PM

1,197,524 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All